Matinas BioPharma DEF 14A: Executive Comp Details
Ticker: MTNB · Form: DEF 14A · Filed: May 12, 2025 · CIK: 1582554
| Field | Detail |
|---|---|
| Company | Matinas Biopharma Holdings, Inc. (MTNB) |
| Form Type | DEF 14A |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, sec-filing, equity-awards
Related Tickers: MTNB
TL;DR
Matinas BioPharma DEF 14A out - exec comp details for 2024, including equity awards for Jerome Jabbour.
AI Summary
Matinas BioPharma Holdings, Inc. filed a DEF 14A on May 13, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to key personnel, such as Jerome Jabbour, and their fair values. It also outlines the company's reporting of compensation elements, including the exclusion and inclusion of option awards and equity values.
Why It Matters
This filing provides transparency into how Matinas BioPharma compensates its top executives, which can influence investor decisions regarding the company's financial health and management's alignment with shareholder interests.
Risk Assessment
Risk Level: medium — DEF 14A filings related to executive compensation can reveal insights into company performance and future strategies, but the direct financial impact is often indirect and depends on broader company performance.
Key Numbers
- 2024 — Fiscal Year End (The period for which executive compensation is reported.)
- 20250513 — Filing Date (The date the DEF 14A was filed with the SEC.)
Key Players & Entities
- Matinas BioPharma Holdings, Inc. (company) — Filer of the DEF 14A
- Jerome Jabbour (person) — Executive mentioned in relation to compensation
- 0001582554 (company) — Central Index Key for Matinas BioPharma Holdings, Inc.
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to disclose executive compensation details for Matinas BioPharma Holdings, Inc. for the fiscal year ending December 31, 2024.
Who is Jerome Jabbour and what is his role in this filing?
Jerome Jabbour is mentioned in relation to compensation, specifically concerning equity awards and their fair values for the fiscal year 2024.
What specific types of compensation are detailed in the filing?
The filing details executive compensation including option awards and equity values, with specific mentions of 'ExclusionOfOptionAwardsMember' and 'InclusionOfEquityValuesMember'.
What is the fiscal year end for Matinas BioPharma Holdings, Inc. as stated in this filing?
The fiscal year end for Matinas BioPharma Holdings, Inc. is December 31, as indicated by the reporting periods.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on May 13, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 12, 2025 by Jerome Jabbour regarding Matinas BioPharma Holdings, Inc. (MTNB).